Fig. 8: Patient DCRs, response durations and serum cytokine levels. | Nature Communications

Fig. 8: Patient DCRs, response durations and serum cytokine levels.

From: Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial

Fig. 8

a Disease control rate in all 31 patients and patients with different cancers. b Duration following initial treatment (n = 31). Patient 36 halted treatment due to severe skin breakdown but resumed treatment after hormonal therapy. Patient 43 died from a lung infection caused by coronavirus disease after three months of SD. Patient 49 was excluded due to receiving other tumour treatments. Nine patients developed new lesions, but the primary lesion was under control. Four patients maintained ongoing responses. c Waterfall plot showing maximum changes from baseline in target lesion size in tumours of patients with different tumour types (n = 31). d Total TCRs and unique TCRs of T cells from the PB of patients who achieved an objective response according to TCR-β CDR3 sequencing (n = 7). Red represents detection at pre-treatment and dark green represents detection at post-treatment. e–j Changes in blood serum cytokine levels in patients after different cycles of anti-PD-1 antibody treatment compared to baseline (n = 31). Dotted lines represent individual patients; the solid line represents the mean of all patients. CR complete response, PR partial response, SD stable disease, PD disease progression. Source data and exact p values are provided as a Source Data file.

Back to article page